Read by QxMD icon Read

cardio- oncology

Sean M Davidson, Sapna Arjun, Maryna V Basalay, Robert M Bell, Daniel I Bromage, Hans Erik Bøtker, Richard D Carr, John Cunningham, Arjun K Ghosh, Gerd Heusch, Borja Ibanez, Petra Kleinbongard, Sandrine Lecour, Helen Maddock, Michel Ovize, Malcolm Walker, Marlene Wiart, Derek M Yellon
Due to its poor capacity for regeneration, the heart is particularly sensitive to the loss of contractile cardiomyocytes. The onslaught of damage caused by ischaemia and reperfusion, occurring during an acute myocardial infarction and the subsequent reperfusion therapy, can wipe out upwards of a billion cardiomyocytes. A similar program of cell death can cause the irreversible loss of neurons in ischaemic stroke. Similar pathways of lethal cell injury can contribute to other pathologies such as left ventricular dysfunction and heart failure caused by cancer therapy...
October 11, 2018: Basic Research in Cardiology
Athanasios Koutsoukis, Argyrios Ntalianis, Evangelos Repasos, Efsthathios Kastritis, Meletios-Athanasios Dimopoulos, Ioannis Paraskevaidis
Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing cardiovascular morbidity and mortality and improving quality of life in cancer survivors. Cancer survival rates have been constantly increasing, mainly because of the advent of new, more potent and targeted therapies. However, many of the new therapies - along with some of the older chemotherapeutic regimens such as anthracyclines - are potentially cardiotoxic, which is reflected increasingly frequently in the published literature...
August 2018: European Cardiology
Steven M Ewer
No abstract text is available yet for this article.
August 2018: European Cardiology
Stephen J H Dobbin, Alan C Cameron, Mark C Petrie, Robert J Jones, Rhian M Touyz, Ninian N Lang
Clinical outcomes for patients with a wide range of malignancies have improved substantially over the last two decades. Tyrosine kinase inhibitors (TKIs) are potent signalling cascade inhibitors and have been responsible for significant advances in cancer therapy. By inhibiting vascular endothelial growth factor receptor (VEGFR)-mediated tumour blood vessel growth, VEGFR-TKIs have become a mainstay of treatment for a number of solid malignancies. However, the incidence of VEGFR-TKI-associated cardiovascular toxicity is substantial and previously under-recognised...
September 18, 2018: Heart: Official Journal of the British Cardiac Society
Michal Laufer-Perl, Matthew Derakhshesh, Assi Milwidsky, Liat Mor, Dor Ravid, Nadav Amrami, Jack Sherez, Gad Keren, Yan Topilsky, Yaron Arbel
Cardiotoxicity from cancer therapy has become a leading cause of morbidity and mortality in cancer survivors. The most commonly used definition is cancer therapeutic related cardiac dysfunction defined as a left ventricular ejection fraction (LVEF) reduction of >10%, to a value below 50%. However, according to the recent American and European Society of Echocardiography, global longitudinal strain (GLS) is the optimal parameter for early detection of subclinical left ventricular dysfunction. The objective of this study was to evaluate the frequency of GLS reduction in patients with active cancer and its correlation to other echocardiographic parameters...
August 20, 2018: American Journal of Cardiology
Nilesh Pareek, Joaquim Cevallos, Pedro Moliner, Mit Shah, Li Ling Tan, Vicki Chambers, A John Baksi, Rajdeep S Khattar, Rakesh Sharma, Stuart D Rosen, Alexander R Lyon
AIMS: Cardio-oncology clinics optimise the cardiovascular status of cancer patients but there is a limited description of their structure, case mix, activity and results. The purpose of this paper is to describe the activity and outcomes of a cardio-oncology service, particularly with respect to supporting optimal cancer treatment and survival. METHODS AND RESULTS: We prospectively studied patients referred to our service from February 2011 to February 2016. New York Heart Association (NYHA) class and parameters of cardiac function were measured at baseline and after optimisation by our service...
September 6, 2018: European Journal of Heart Failure
Jenica N Upshaw
Patients with breast cancer have higher rates of cardiovascular disease than age-matched controls. Anthracyclines and trastuzumab increase the risk of heart failure (HF) and radiation increases the risk of ischemic heart disease, valvular disease and HF. Older age, low normal ejection fraction, history of coronary artery disease (CAD), cardiac risk factors, higher cumulative anthracycline exposure, combination anthracycline and trastuzumab and/or radiation all increase the risk of cardiac events post treatment...
August 2018: Gland Surgery
A J Teske, M Linschoten, J A M Kamphuis, W R Naaktgeboren, T Leiner, E van der Wall, J Kuball, A van Rhenen, P A Doevendans, M J Cramer, F W Asselbergs
Recent advances in the early detection and treatment of cancer have led to increasing numbers of cancer survivors worldwide. Nonetheless, despite major improvements in the outcome of these patients, long-term side effects of radio- and chemotherapy affect both patient survival and quality of life, independent of the oncological prognosis. Chemotherapy-related cardiac dysfunction is one of the most notorious short-term side effects of anticancer treatment, occurring in ~10% of patients. Progression to overt heart failure carries a strikingly poor prognosis with a 2-year mortality rate of 60%...
August 23, 2018: Netherlands Heart Journal
Muhammad Sardar, Nasreen Shaikh, Saad Ullah Malik, Faiz Anwer, Patrick Lee, David Sharon, Margaret Hh Eng
BACKGROUND: Despite cancer being the second most common cause of death in the United States, more people are living longer after the diagnosis of cancer than before. Healthcare workers will be treating an increasing number of patients with cancer. Various studies have identified predictors of cardiac arrest in the general population, however, none have been done to identify such factors in cancer patients who form a more vulnerable group with lower survival rate following cardiac arrest...
June 18, 2018: Curēus
Elizabeth Riddell, Daniel Lenihan
Major advances in cancer therapy have resulted in an unprecedented improvement in patient survival for many cancers. Partially as a consequence of increased longevity, it has become evident that the cardiovascular system is frequently impacted by chemotherapy, radiation, and particularly certain targeted therapy. Cardiotoxicity continues to be a dose-limiting side effect of many chemotherapeutic agents including the anthracyclines. Early identification of patients at increased risk of cardiotoxicity or detecting cardiac injury at the earliest point will allow for initiation of cardio-protective strategies and hopefully prevent or reduce the need to modify life-saving cancer therapies...
July 18, 2018: Current Problems in Cancer
Richard M Steingart, Y Chandrashekhar, Thomas H Marwick
No abstract text is available yet for this article.
August 2018: JACC. Cardiovascular Imaging
Jennifer Liu, Jose Banchs, Negareh Mousavi, Juan Carlos Plana, Marielle Scherrer-Crosbie, Paaladinesh Thavendiranathan, Ana Barac
Early recognition of cancer therapy-related cardiac dysfunction (CTRCD) provides an opportunity to mitigate cardiac injury and risk of developing late cardiac events. Echocardiography serves as the cornerstone in the detection and surveillance of CTRCD in patients during and after cancer therapy. Guidelines from professional societies and regulatory agencies have been published on approaches to surveillance, diagnosis, and treatment of CTRCD, although adoption as standard of care remains limited given the lack of evidence on the prognostic value of asymptomatic left ventricular (LV) dysfunction in the oncology population...
August 2018: JACC. Cardiovascular Imaging
Patrizio Lancellotti, Thomas M Suter, Teresa López-Fernández, Maurizio Galderisi, Alexander R Lyon, Peter Van der Meer, Alain Cohen Solal, Jose-Luis Zamorano, Guy Jerusalem, Marie Moonen, Victor Aboyans, Jeroen J Bax, Riccardo Asteggiano
Aims: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer...
August 6, 2018: European Heart Journal
C G Nebigil, L Désaubry
Cardio-oncology is a new discipline that focuses on understanding, detection, monitoring and treating cardiovascular disease during and after cancer treatment. The development of this emerging field is based on an interdisciplinary collaboration between cardiology and oncology researchers and clinicians. Cardio-oncology aims at identifying how cancer therapies impact cardiovascular homeostasis, particular risk factors, diagnostic biomarkers and novel therapeutic approaches to help to effectively detect, prevent and cure the cardiotoxicity...
July 31, 2018: Annales Pharmaceutiques Françaises
Peggy M Kostakou, Nikos T Kouris, Vassilios S Kostopoulos, Dimitrios S Damaskos, Christoforos D Olympios
Cardio-oncology is a new field of interest in cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease occurring as a side effect of chemotherapy and radiotherapy. Both cancer treatment modalities can cause cardiac dysfunction, a major cause of morbidity and mortality in the oncologic population. It is necessary to periodically monitor cancer patients under treatment, especially those receiving anthracyclines and trastuzumab (monoclonal antibody), using mainly 3D echocardiography to calculate left ventricular ejection fraction and to estimate myocardial deformation...
August 2, 2018: Heart Failure Reviews
Anna C Bibby, Patrick Dorn, Ioannis Psallidas, Jose M Porcel, Julius Janssen, Marios Froudarakis, Dragan Subotic, Phillippe Astoul, Peter Licht, Ralph Schmid, Arnaud Scherpereel, Najib M Rahman, Giuseppe Cardillo, Nick A Maskell
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature...
July 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
Marijana Tadic, Cesare Cuspidi, Dragan Vasic, Peter L M Kerkhof
Cardiovascular disease may be associated with several comorbidities, including diabetes mellitus, thyroid disorders, and the metabolic syndrome, which are predominantly observed in women and often starting at particular ages. In addition, common treatment options for carcinomas frequently seen in women may induce serious cardiotoxic effects. We review the scope of the problem, the pathophysiologic mechanisms involved, as well as the resulting abnormalities regarding cardiac structure and function as observed by using imaging techniques...
2018: Advances in Experimental Medicine and Biology
Tochi M Okwuosa, Nicole Prabhu, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Kim A Williams, Agne Paner
No abstract text is available yet for this article.
July 10, 2018: Journal of the American College of Cardiology
Joseph J Maleszewski, Melanie C Bois, John P Bois, Philip M Young, John M Stulak, Kyle W Klarich
The intersection of oncological and cardiovascular diseases is an increasingly recognized phenomenon. This recognition has led to the emergence of cardio-oncology as a true subspecialty. This field is not simply limited to primary cardiac tumors or complications of chemotherapeutic medications. Rather, it also encompasses metastatic cardiovascular complications and secondary cardiovascular effects of the underlying neoplasia. This review will broadly cover primary and metastatic cardiac neoplasms, as well as secondary cardiovascular effects of extracardiac neoplasia (e...
July 10, 2018: Journal of the American College of Cardiology
Juan Lopez-Mattei, Peter Kim, Cezar Iliescu
No abstract text is available yet for this article.
June 19, 2018: Trends in Cardiovascular Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"